PEOPLE - Osiris Therapeutics (US) forms new senior management team:
This article was originally published in Clinica
US company Osiris Therapeutics has formed a senior management team which will focus on the commercialisation of its adult stem cell products. It includes Dr Annemarie Moseley as senior vice-president of clinical and regulatory affairs; Dr Daniel Marshak, senior vice-president and chief scientific officer; John Coker, vice-president and chief financial officer, secretary and treasurer; Dr Stewart Craig, vice-president of development and operations; Dr Robert Deans, vice-president of applied research; Dr Stephen Gordon, vice-president of advanced technology management; and Kenneth Moseley, vice-president of patents and business development.
You may also be interested in...
With Brexit less than a month old, Germany’s medtech industry has renewed its push for an MRA between the EU and UK in medtech regulation.
Days after a senior Chinese government official offered free COVID-19 vaccines to the Philippines government, the country’s medicines regulator said the donated jabs would need an emergency approval before they can be used on the public.
Interview: recently appointed CEO Richard Francis will apply his background in big pharma and biotech to building the UK start-up Purespring Therapeutics with a focus on using gene therapy technology to target renal diseases.